Role of pharmacogenetics in chemotherapy of colorectal cancers
Clinical implications associated with polymorphisms in drug-metabolizing genes involved in the chemotherapy of colorectal cancers (5-flurorouracil, oxaliplatin and irinotecan) are reviewed. Treatments of colorectal cancers have been greatly improved last years but patients respond differently to ide...
Gespeichert in:
| Veröffentlicht in: | La revue de medecine interne 2007-09, Vol.28 (9), p.594 |
|---|---|
| Hauptverfasser: | , , , , , , |
| Format: | Artikel |
| Sprache: | fre |
| Schlagworte: | |
| Online-Zugang: | Volltext |
| Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
| container_end_page | |
|---|---|
| container_issue | 9 |
| container_start_page | 594 |
| container_title | La revue de medecine interne |
| container_volume | 28 |
| creator | Ceppa, F Fontan, E Cremades, S Bihannic, R Bousquet, A Beauvillain, L Burnat, P |
| description | Clinical implications associated with polymorphisms in drug-metabolizing genes involved in the chemotherapy of colorectal cancers (5-flurorouracil, oxaliplatin and irinotecan) are reviewed.
Treatments of colorectal cancers have been greatly improved last years but patients respond differently to identical medication. Genetic polymorphisms are one of the major causes of these individual responses to drugs associated with sometimes severe adverse effects. Pharmacogenetics is based on all polymorphisms that determine genetic human diversity associated with variable response to anticancer drugs.
Morbidity and mortality related to toxicity or inefficacy of these drugs could be reduced by analyzing the pharmacogenetic profile of patients before treatment. Results should be integrated in protocols for monitoring and assessment the dosage of drugs. |
| doi_str_mv | 10.1016/j.revmed.2007.03.005 |
| format | Article |
| fullrecord | <record><control><sourceid>pubmed</sourceid><recordid>TN_cdi_pubmed_primary_17624636</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>17624636</sourcerecordid><originalsourceid>FETCH-LOGICAL-p139t-75b30898ec10d40a6db5c40320468828ddd00deb403fc1df3152ba3de3bd78433</originalsourceid><addsrcrecordid>eNo1j9tKxDAURfOgOOPoH4j0BxpPctI0fRFk8AYDgujzkMup7dA2Ja3C_L0V9WnDZrFgMXYlgAsQ-ubAE331FLgEKDkgByhO2BqkMrnRGlfsfJoOALDQ1RlbiVJLpVGv2e1r7CiLdTY2NvXWxw8aaG79lLVD5hvq49xQsuPxh_Gxi4n8bLvM28FTmi7YaW27iS7_dsPeH-7ftk_57uXxeXu3y0eB1ZyXhUMwlSEvICiwOrjCK0AJShsjTQgBIJBbrtqLUKMopLMYCF0ojULcsOtf7_jpls79mNrepuP-PwS_AdY_SrQ</addsrcrecordid><sourcetype>Index Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype></control><display><type>article</type><title>Role of pharmacogenetics in chemotherapy of colorectal cancers</title><source>MEDLINE</source><source>Access via ScienceDirect (Elsevier)</source><creator>Ceppa, F ; Fontan, E ; Cremades, S ; Bihannic, R ; Bousquet, A ; Beauvillain, L ; Burnat, P</creator><creatorcontrib>Ceppa, F ; Fontan, E ; Cremades, S ; Bihannic, R ; Bousquet, A ; Beauvillain, L ; Burnat, P</creatorcontrib><description>Clinical implications associated with polymorphisms in drug-metabolizing genes involved in the chemotherapy of colorectal cancers (5-flurorouracil, oxaliplatin and irinotecan) are reviewed.
Treatments of colorectal cancers have been greatly improved last years but patients respond differently to identical medication. Genetic polymorphisms are one of the major causes of these individual responses to drugs associated with sometimes severe adverse effects. Pharmacogenetics is based on all polymorphisms that determine genetic human diversity associated with variable response to anticancer drugs.
Morbidity and mortality related to toxicity or inefficacy of these drugs could be reduced by analyzing the pharmacogenetic profile of patients before treatment. Results should be integrated in protocols for monitoring and assessment the dosage of drugs.</description><identifier>ISSN: 0248-8663</identifier><identifier>DOI: 10.1016/j.revmed.2007.03.005</identifier><identifier>PMID: 17624636</identifier><language>fre</language><publisher>France</publisher><subject>Acetylcholinesterase - genetics ; Antineoplastic Agents - adverse effects ; Antineoplastic Agents - therapeutic use ; Butyrylcholinesterase - genetics ; Camptothecin - adverse effects ; Camptothecin - analogs & derivatives ; Colorectal Neoplasms - drug therapy ; Colorectal Neoplasms - enzymology ; Colorectal Neoplasms - genetics ; Dihydrouracil Dehydrogenase (NADP) - genetics ; Humans ; Methylenetetrahydrofolate Reductase (NADPH2) - genetics ; Organoplatinum Compounds - adverse effects ; Pharmacogenetics - methods ; Polymorphism, Genetic</subject><ispartof>La revue de medecine interne, 2007-09, Vol.28 (9), p.594</ispartof><lds50>peer_reviewed</lds50><woscitedreferencessubscribed>false</woscitedreferencessubscribed></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><link.rule.ids>314,780,784,27924,27925</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/17624636$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Ceppa, F</creatorcontrib><creatorcontrib>Fontan, E</creatorcontrib><creatorcontrib>Cremades, S</creatorcontrib><creatorcontrib>Bihannic, R</creatorcontrib><creatorcontrib>Bousquet, A</creatorcontrib><creatorcontrib>Beauvillain, L</creatorcontrib><creatorcontrib>Burnat, P</creatorcontrib><title>Role of pharmacogenetics in chemotherapy of colorectal cancers</title><title>La revue de medecine interne</title><addtitle>Rev Med Interne</addtitle><description>Clinical implications associated with polymorphisms in drug-metabolizing genes involved in the chemotherapy of colorectal cancers (5-flurorouracil, oxaliplatin and irinotecan) are reviewed.
Treatments of colorectal cancers have been greatly improved last years but patients respond differently to identical medication. Genetic polymorphisms are one of the major causes of these individual responses to drugs associated with sometimes severe adverse effects. Pharmacogenetics is based on all polymorphisms that determine genetic human diversity associated with variable response to anticancer drugs.
Morbidity and mortality related to toxicity or inefficacy of these drugs could be reduced by analyzing the pharmacogenetic profile of patients before treatment. Results should be integrated in protocols for monitoring and assessment the dosage of drugs.</description><subject>Acetylcholinesterase - genetics</subject><subject>Antineoplastic Agents - adverse effects</subject><subject>Antineoplastic Agents - therapeutic use</subject><subject>Butyrylcholinesterase - genetics</subject><subject>Camptothecin - adverse effects</subject><subject>Camptothecin - analogs & derivatives</subject><subject>Colorectal Neoplasms - drug therapy</subject><subject>Colorectal Neoplasms - enzymology</subject><subject>Colorectal Neoplasms - genetics</subject><subject>Dihydrouracil Dehydrogenase (NADP) - genetics</subject><subject>Humans</subject><subject>Methylenetetrahydrofolate Reductase (NADPH2) - genetics</subject><subject>Organoplatinum Compounds - adverse effects</subject><subject>Pharmacogenetics - methods</subject><subject>Polymorphism, Genetic</subject><issn>0248-8663</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2007</creationdate><recordtype>article</recordtype><sourceid>EIF</sourceid><recordid>eNo1j9tKxDAURfOgOOPoH4j0BxpPctI0fRFk8AYDgujzkMup7dA2Ja3C_L0V9WnDZrFgMXYlgAsQ-ubAE331FLgEKDkgByhO2BqkMrnRGlfsfJoOALDQ1RlbiVJLpVGv2e1r7CiLdTY2NvXWxw8aaG79lLVD5hvq49xQsuPxh_Gxi4n8bLvM28FTmi7YaW27iS7_dsPeH-7ftk_57uXxeXu3y0eB1ZyXhUMwlSEvICiwOrjCK0AJShsjTQgBIJBbrtqLUKMopLMYCF0ojULcsOtf7_jpls79mNrepuP-PwS_AdY_SrQ</recordid><startdate>200709</startdate><enddate>200709</enddate><creator>Ceppa, F</creator><creator>Fontan, E</creator><creator>Cremades, S</creator><creator>Bihannic, R</creator><creator>Bousquet, A</creator><creator>Beauvillain, L</creator><creator>Burnat, P</creator><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope></search><sort><creationdate>200709</creationdate><title>Role of pharmacogenetics in chemotherapy of colorectal cancers</title><author>Ceppa, F ; Fontan, E ; Cremades, S ; Bihannic, R ; Bousquet, A ; Beauvillain, L ; Burnat, P</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-p139t-75b30898ec10d40a6db5c40320468828ddd00deb403fc1df3152ba3de3bd78433</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>fre</language><creationdate>2007</creationdate><topic>Acetylcholinesterase - genetics</topic><topic>Antineoplastic Agents - adverse effects</topic><topic>Antineoplastic Agents - therapeutic use</topic><topic>Butyrylcholinesterase - genetics</topic><topic>Camptothecin - adverse effects</topic><topic>Camptothecin - analogs & derivatives</topic><topic>Colorectal Neoplasms - drug therapy</topic><topic>Colorectal Neoplasms - enzymology</topic><topic>Colorectal Neoplasms - genetics</topic><topic>Dihydrouracil Dehydrogenase (NADP) - genetics</topic><topic>Humans</topic><topic>Methylenetetrahydrofolate Reductase (NADPH2) - genetics</topic><topic>Organoplatinum Compounds - adverse effects</topic><topic>Pharmacogenetics - methods</topic><topic>Polymorphism, Genetic</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Ceppa, F</creatorcontrib><creatorcontrib>Fontan, E</creatorcontrib><creatorcontrib>Cremades, S</creatorcontrib><creatorcontrib>Bihannic, R</creatorcontrib><creatorcontrib>Bousquet, A</creatorcontrib><creatorcontrib>Beauvillain, L</creatorcontrib><creatorcontrib>Burnat, P</creatorcontrib><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><jtitle>La revue de medecine interne</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Ceppa, F</au><au>Fontan, E</au><au>Cremades, S</au><au>Bihannic, R</au><au>Bousquet, A</au><au>Beauvillain, L</au><au>Burnat, P</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Role of pharmacogenetics in chemotherapy of colorectal cancers</atitle><jtitle>La revue de medecine interne</jtitle><addtitle>Rev Med Interne</addtitle><date>2007-09</date><risdate>2007</risdate><volume>28</volume><issue>9</issue><spage>594</spage><pages>594-</pages><issn>0248-8663</issn><abstract>Clinical implications associated with polymorphisms in drug-metabolizing genes involved in the chemotherapy of colorectal cancers (5-flurorouracil, oxaliplatin and irinotecan) are reviewed.
Treatments of colorectal cancers have been greatly improved last years but patients respond differently to identical medication. Genetic polymorphisms are one of the major causes of these individual responses to drugs associated with sometimes severe adverse effects. Pharmacogenetics is based on all polymorphisms that determine genetic human diversity associated with variable response to anticancer drugs.
Morbidity and mortality related to toxicity or inefficacy of these drugs could be reduced by analyzing the pharmacogenetic profile of patients before treatment. Results should be integrated in protocols for monitoring and assessment the dosage of drugs.</abstract><cop>France</cop><pmid>17624636</pmid><doi>10.1016/j.revmed.2007.03.005</doi></addata></record> |
| fulltext | fulltext |
| identifier | ISSN: 0248-8663 |
| ispartof | La revue de medecine interne, 2007-09, Vol.28 (9), p.594 |
| issn | 0248-8663 |
| language | fre |
| recordid | cdi_pubmed_primary_17624636 |
| source | MEDLINE; Access via ScienceDirect (Elsevier) |
| subjects | Acetylcholinesterase - genetics Antineoplastic Agents - adverse effects Antineoplastic Agents - therapeutic use Butyrylcholinesterase - genetics Camptothecin - adverse effects Camptothecin - analogs & derivatives Colorectal Neoplasms - drug therapy Colorectal Neoplasms - enzymology Colorectal Neoplasms - genetics Dihydrouracil Dehydrogenase (NADP) - genetics Humans Methylenetetrahydrofolate Reductase (NADPH2) - genetics Organoplatinum Compounds - adverse effects Pharmacogenetics - methods Polymorphism, Genetic |
| title | Role of pharmacogenetics in chemotherapy of colorectal cancers |
| url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2024-12-30T22%3A07%3A30IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-pubmed&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Role%20of%20pharmacogenetics%20in%20chemotherapy%20of%20colorectal%20cancers&rft.jtitle=La%20revue%20de%20medecine%20interne&rft.au=Ceppa,%20F&rft.date=2007-09&rft.volume=28&rft.issue=9&rft.spage=594&rft.pages=594-&rft.issn=0248-8663&rft_id=info:doi/10.1016/j.revmed.2007.03.005&rft_dat=%3Cpubmed%3E17624636%3C/pubmed%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_id=info:pmid/17624636&rfr_iscdi=true |